Compare UNTY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | INBX |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.4M | 430.2M |
| IPO Year | 1997 | 2020 |
| Metric | UNTY | INBX |
|---|---|---|
| Price | $56.14 | $86.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $59.67 | N/A |
| AVG Volume (30 Days) | 37.5K | ★ 232.9K |
| Earning Date | 01-14-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 35.12 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $121,970,000.00 | $1,400,000.00 |
| Revenue This Year | $24.41 | $563.00 |
| Revenue Next Year | $11.16 | $230.77 |
| P/E Ratio | $10.69 | ★ N/A |
| Revenue Growth | ★ 20.98 | N/A |
| 52 Week Low | $36.65 | $10.81 |
| 52 Week High | $57.24 | $94.47 |
| Indicator | UNTY | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 75.28 | 59.17 |
| Support Level | $55.35 | $74.80 |
| Resistance Level | $57.24 | $94.47 |
| Average True Range (ATR) | 1.76 | 6.36 |
| MACD | 0.33 | -1.27 |
| Stochastic Oscillator | 86.16 | 62.68 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.